Melanoma research gets a funding boost from NHMRC

Melanoma research gets a funding boost from NHMRC

9 December 2016

Research projects led by Melanoma Institute Australia (MIA) have been awarded almost $6 million in the latest National Health and Medical Research Council (NHMRC) funding round which will enable vital progression of research into melanoma prevention and treatment. Projects led by MIA researchers have been awarded the highly competitive funding:

  • Professor Georgina Long (MIA and The University of Sydney) received a Practitioner Fellowship (5 years) to investigate the underlying biology of patients’ responses to treatment. By understanding why some patients respond well to therapies when others develop resistance will help us develop tests to ensure the best possible treatment is given to each individual patient. In addition, it will also help identify the ideal drug therapy combinations to improve patient outcomes further or prevent metastatic melanoma altogether.
  • Professor Nicholas Hayward (MIA and QIMR Berghofer) received a Research Fellowship (3 years) to investigate genetic predisposition to melanoma in the general population and predisposed families, and the genes involved in traits underlying melanoma development. He was also awarded a Project Grant (5 years) to conduct a comprehensive genetic analysis of acral melanoma to ultimately identify new drug targets to treat this disease. Although an uncommon subtype of melanoma, acral melanoma has a bad prognosis and has been poorly characterised at the molecular level.
  • Professor Helen Rizos (MIA and Macquarie University) received two Project Grants to investigate the cell biology of melanoma. These project grants involved a team of chief investigators from MIA, who have collaborated on melanoma response and resistance for many years, including Professor Richard Kefford, Professor Georgina Long, Dr Matteo Carlino, Dr Alexander Menzies and Dr Xu Dong Zhang, and new collaborator Professor Barbara Fazekas de St Groth. The first Project Grant (4 years) will be used to investigate the mechanisms of response and resistance to combination immunotherapies in order to enhance the duration and rate of patient response. The second Project Grant (4 years) will use tumour samples of patients who have developed resistance to immunotherapies to determine the underlying mechanisms involved. This information will accelerate the identification of new combination therapies to improve patient outcomes.
  • Associate Professor Anne Cust (MIA and The University of Sydney) was awarded a 4-year Project Grant to improve skin cancer prevention. Her research will evaluate whether they can improve skin cancer prevention behaviours by giving personalised information about melanoma genetic risk. They will also explore the psycho-social, ethical and economic implications of receiving this information, with the ultimate aim to positively influence the future of skin cancer prevention in Australia.


To date, the 2016 NHMRC Grant Application Round has resulted in the commitment of more than $703 million to fund health and medical research across Australia.​

MIA contributes to major research breakthrough which pioneers a new way of treating cancer
01 Jun 2015

MIA contributes to major research breakthrough which pioneers a new way of treating cancer

The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.

Q&A with our Clinical Research Fellow
26 May 2015

Q&A with our Clinical Research Fellow

We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam

International Clinical Trials Day marked
20 May 2015

International Clinical Trials Day marked

Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research. 

5 minutes with Practice Manager Sherrie D'Souza
15 May 2015

5 minutes with Practice Manager Sherrie D'Souza

We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role. 

Associate Professor Georgina Long has won the InStyle Women In Style Award
14 May 2015

Associate Professor Georgina Long has won the InStyle Women In Style Award

Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category. 

The Federal Government's 2015-16 Budget announcements benefit research
14 May 2015

The Federal Government's 2015-16 Budget announcements benefit research

The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding. 

Professor Thompson made an honorary member of the American Surgical Association
01 May 2015

Professor Thompson made an honorary member of the American Surgical Association

The Association's members include prominent surgeons from around the world. 

MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
20 Apr 2015

MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients

This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers. 

Anti-PD1 immunotherapy pembrolizumab (KEYTRUDA®) has been registered by the TGA
20 Apr 2015

Anti-PD1 immunotherapy pembrolizumab (KEYTRUDA® ) has been registered by the TGA

Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.

MIA's Autumn Newsletter
12 Apr 2015

MIA's Autumn Newsletter

Our Autumn newsletter has been published and we have our digital version online now. 

Professor John Thompson appointed to Australian Academy of Health and Medical Sciences
31 Mar 2015

Professor John Thompson appointed to Australian Academy of Health and Medical Sciences

Professor John Thompson, Executive Director at Melanoma Institute Australia, was one of 116 fellows appointed to the new Australian Academy of Health and Medical Sciences at a ceremony in Canberra on the 25th March.

Melanoma Institute part of $14m melanoma project grant
25 Mar 2015

Melanoma Institute part of $14m melanoma project grant

Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.

Melanoma March Bibs
19 Mar 2015

Melanoma March Bibs

If you would like to download a bib for your Melanoma March, we have a selection for you to choose from, print and bring along with you on the day. 

Manly Melanoma March
17 Mar 2015

Manly Melanoma March

Manly Melanoma March has changed to a new location. 

Q&A with Melanoma March Fundraisers
10 Mar 2015

Q&A with Melanoma March Fundraisers

We did a short Q&A with two sisters who are raising funds for Melanoma March after sadly losing their mother in 2009. This is their second march and they have shared with us their fundraising tips. 

Research Director Graham Mann explains where Melanoma March funds are going
10 Mar 2015

Research Director Graham Mann explains where Melanoma March funds are going

We want to share with you what your valuable Melanoma March donation and fundraising goes towards and our Research Director, Graham Mann explains the national research project the funds will be going towards.

First patient recruited to the EAGLE FM Trial
09 Mar 2015

First patient recruited to the EAGLE FM Trial

Evaluation of Groin Lymphadenectomy Extent for Metastatic Melanoma (EAGLE FM) clinical trial has recruited its first patient.  

Online Comments to the Pharmaceutical Benefits Advisory Committee
09 Feb 2015

Online Comments to the Pharmaceutical Benefits Advisory Committee

You are invited to provide comments for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC will consider the registration of the anti-PD1 drug, Keytruda (pembrolizumab) at the next meeting in March.

A man of commitment
06 Feb 2015

A man of commitment

Melanoma patient Joel Allsop was congratulated today on completing his participation in the international surgical clinical trial, known as MSLT-II. He was the first person in the world to complete the 10 years of follow-up for this trial.